Home treatment with bypassing products in inhibitor patients: A 7.5-year experience

Haemophilia

Volumn 15, Issue 3, 2009, Pages 727-732

  Holme, Pål A ^a   Glomstein, A ^b   Gronhaug S ^b   Tjonnfjord G E ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Activated prothrombin complex concentrates; Bypassing products; Factor VIII inhibitor; Haemophilia A with inhibitors; Home treatment; Recombinant activated factor VII

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE CONTROL; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEASIBILITY STUDY; FOLLOW UP; HEMARTHROSIS; HEMOPHILIA A; HEMOSTASIS; HOME CARE; HUMAN; LONG TERM CARE; MUSCLE BLEEDING; PATIENT SELECTION; PRIORITY JOURNAL; PRURITUS; SINGLE DRUG DOSE; SKIN BLEEDING; THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; COST-BENEFIT ANALYSIS; FACTOR VIIA; FEMALE; HEMARTHROSIS; HEMOPHILIA A; HEMOSTATICS; HOME CARE SERVICES; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65449155974     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02017.x     Document Type: Article

References (27)

1. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: Emerging data and clinical direction. Am J Hematol 2004; 77: 187-93.
2. Kulkarni R, Aledort LM, Berntorp E et al. Therapeutic choices for patients with hemophilia and high-titer inhibitors. Am J Hematol 2001; 67: 240-6.
3. Hilgartner MW, Knatterud GL. The use of factor eight inhibitor by-passing activity (FEIBA) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36-40.
4. Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: A systematic review. Haemophilia 2003; 9: 464-520.
5. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295: 293-8.
6. Young G, Aledort LM. Therapy for haemophilia: Recent advances and goals for the future. Expert Opin Emerg Drugs 2005; 10: 173-84.
7. Teitel J, Berntorp E, Collins P et al. A systematic approach to controlling bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007; 13: 256-63.
8. Tjønnfjord G. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 2004; 10: 174-8.
9. Tjønnfjord G, Holme PA. Factor eight inhibitor bypassing activity (FEIBA) in the management of bleeds in hemophilia patients with high-titre inhibitors. Vasc Health Risk Manag 2007; 3: 527-31.
10. Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: The FEIBA NovoSeven comparative (FENOC) study. Blood 2007; 109: 546-51.
11. Lusher JM. Early treatment with recombinant factor VIIa results in a greater efficacy with less product. Eur J Haematol Suppl 1998; 63: 7-10.
12. Lusher JM. Acute hemarthroses: The benefits of early versus late treatment with recombinant activated factor VIIa. Blood Coagul Fibrinolysis 2000; 11: 45-9.
13. Hooiveld M, Roosendaal G, Vianen M, van den Berg M, Bijlsma J, Lafeber F. Blood-induced joint damage: Longterm effects in vitro and in vivo. J Rheumatol 2003; 30: 339-44.
14. Hooiveld M, Roosendaal G, van den Berg M, Bijlsma J, Lafeber F. Haemoglobin-derived iron-dependent hydroxyl radical formation in blood-induced joint damage: An in vitro study. Rheumatology 2003; 42: 784-90.
15. Key NS. Efficacy of recombinant activated factor VIIa when administered in the home to control joint, muscle, and mucocutaneous bleeds in haemophilia patients with inhibitors. Blood Coagul Fibrinolysis 1998; 9: 111-4.
16. Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: The advantages of early imtervention. Br J Haematol 1999; 104: 22-6.
17. Markova I, Forbes CD, Rowlands A, Pettigrew A, Willoughby M. The haemophilic patient's self-perception of changes in health and life-style arising from self-treatment. Int J Rehabil Res 1983; 6: 11-8.
18. Donfield SM, Astermark J, Lail AE, Gilbert SA, Berntorp E. Value added: increasing the power to assess treatment outcome in joint haemorrhages. Haemophilia 2008; 14: 276-80.
19. Ross-Degnan D, Soumerai SB. Hemophilia home treatment, economic analysis and implications for health policy. Int J Technol Assess Health Care 1995; 11: 327-44.
20. Negrier C, Group FFs. FEIBA VH in Home Treatment: A 3-Year Prospective Experience. The Hague: Abstract at XXIII International Congress of the World Federation of Hemophilia, 1998.
21. Glomstein A, Grønhaug S, Tjønnfjord G. Home Treatment with FEIBA, the Norwegian Experience. Sevilla: Abstract at XXV International Congress of the World Federation of Haemophilia, 2002.
22. Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
23. Ingerslev J, Thykjaer H, Scheibel E. Approaches towards successful home treatment in patients with inhibitors. Eur J Haematol 1998; 61: 11-4.
24. Ingerslev J, Thykjaer H, Kudsk Jensen O, Fredberg U. Home treatment with recombinant activated factor VII: Results from one centre. Blood Coagul Fibrinolysis 1998; 9: 107-10.
25. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. Thromb Haemost 2006; 95: 600-5.
26. Young G, Shafer F, Rojas P, Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: A randomized comparison. Haemophilia 2008; 14: 287-94.
27. Lusher JM. Recombinant activated factor VII for treatment of intramuscular haemorrhages: A comparison of early versus late treatment. Blood Coagul Fibrinolysis 1998; 9: 111-4.